 <h1>Durvalumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to durvalumab: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, durvalumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking durvalumab:</p><p>
<i>More common</i>
</p><ul>
<li>Bladder pain</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>bloody or cloudy urine</li>
<li>depressed mood</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty having a bowel movement</li>
<li>dry skin and hair</li>
<li>feeling cold</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>hair loss</li>
<li>hoarseness or husky voice</li>
<li>lower back or side pain</li>
<li>muscle cramps and stiffness</li>
<li>pain</li>
<li>rapid weight gain</li>
<li>slowed heartbeat</li>
<li>stomach cramps</li>
<li>tenderness</li>
<li>tingling of the hands or feet</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>watery or bloody diarrhea</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest pain</li>
<li>chills</li>
<li>cough</li>
<li>dark urine</li>
<li>difficult breathing</li>
<li>general feeling of discomfort or illness</li>
<li>general tiredness and weakness</li>
<li>light-colored stools</li>
<li>nausea</li>
<li>nervousness</li>
<li>sensitivity to heat</li>
<li>sweating</li>
<li>thickening of bronchial secretions</li>
<li>trouble sleeping</li>
<li>upper right abdominal or stomach pain</li>
<li>vomiting</li>
<li>weight loss</li>
<li>yellow eyes and skin</li>
</ul><p>
<i>Less common or rare</i>
</p><ul>
<li>Back, leg, or stomach pains</li>
<li>black, tarry stools</li>
<li>bleeding gums</li>
<li>bloody nose</li>
<li>blurred vision or other changes in vision</li>
<li>chest tightness</li>
<li>eye redness, irritation, or pain</li>
<li>general body swelling</li>
<li>headache</li>
<li>heavier menstrual periods</li>
<li>loss of appetite</li>
<li>nosebleeds</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>redness of the eye</li>
<li>sensitivity of the eye to light</li>
<li>skin rash</li>
<li>sore throat</li>
<li>stiff neck or back</li>
<li>tearing</li>
<li>unusual bleeding or bruising</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Dizziness</li>
<li>drowsiness</li>
<li>fainting</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of durvalumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Decreased appetite</li>
<li>muscle or joint pain</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to durvalumab: intravenous solution</i></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Immune-mediated endocrinopathies (e.g., hypothyroidism, hyperthyroidism, adrenal insufficiency, type 1 diabetes mellitus, hypophysitis/hypopituitarism)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (dermatitis, dermatitis acneiform, dermatitis psoriasiform, psoriasis, rash maculopapular, rash pruritic, rash papular, rash pustular, skin toxicity, eczema, erythema, erythema multiforme, rash erythematous, acne, lichen planus) (11%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Immune-related myocarditis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphopenia (11%)</p>
<p><b>Common</b> (1% to 10%): Anemia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (e.g., cystitis, candiduria, urosepsis) (15%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (21%), nausea (16%), abdominal pain (upper, lower, flank) (14%), diarrhea/colitis (13%)</p>
<p><b>Common</b> (1% to 10%): Dehydration</p>
<p><b>Frequency not reported</b>: Immune-mediated colitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Liver injury, immune-mediated hepatitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased ASO, increased ALT, hyperbilirubinemia</p>
<p><b>Frequency not reported</b>: Immune-mediated hepatitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite/hypophagia (19%), hyponatremia (12%)</p>
<p><b>Common</b> (1% to 10%): Deterioration of general physical health, increased alkaline phosphatase, hypermagnesemia, hypercalcemia, hyperglycemia, neutropenia, hyperkalemia, hypoalbuminemia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion-related reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Infections (e.g., sepsis, necrotizing fasciitis, osteomyelitis)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Uveitis and keratitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (e.g., back pain, musculoskeletal chest pain, musculoskeletal pain and discomfort, myalgia, neck pain) (24%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Pyrexia/tumor associated fever</p>
<p><b>Uncommon</b> (0.1% to 1%): Immune-related aseptic meningitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (e.g., asthenia, lethargy, malaise) (39%), peripheral edema (e.g., edema, localized edema, edema peripheral, lymphedema, peripheral swelling, scrotal edema, scrotal swelling) (15%), pyrexia/tumor associated fever (14%)</p>
<p><b>Common</b> (1% to 10%): Embryofetal toxicity<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Acute kidney injury, increased creatinine<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea/exertional dyspnea (24%), cough/productive cough (10%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Immune-mediated pneumonitis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What type of drug is Imfinzi?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about durvalumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: anti-PD-1 monoclonal antibodies</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Durvalumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Imfinzi</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
<li>Small Cell Lung Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to durvalumab: intravenous solution</i></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Immune-mediated endocrinopathies (e.g., hypothyroidism, hyperthyroidism, adrenal insufficiency, type 1 diabetes mellitus, hypophysitis/hypopituitarism)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (dermatitis, dermatitis acneiform, dermatitis psoriasiform, psoriasis, rash maculopapular, rash pruritic, rash papular, rash pustular, skin toxicity, eczema, erythema, erythema multiforme, rash erythematous, acne, lichen planus) (11%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Immune-related myocarditis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphopenia (11%)</p><p><b>Common</b> (1% to 10%): Anemia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (e.g., cystitis, candiduria, urosepsis) (15%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (21%), nausea (16%), abdominal pain (upper, lower, flank) (14%), diarrhea/colitis (13%)</p><p><b>Common</b> (1% to 10%): Dehydration</p><p><b>Frequency not reported</b>: Immune-mediated colitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Liver injury, immune-mediated hepatitis</p><p><b>Uncommon</b> (0.1% to 1%): Increased ASO, increased ALT, hyperbilirubinemia</p><p><b>Frequency not reported</b>: Immune-mediated hepatitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite/hypophagia (19%), hyponatremia (12%)</p><p><b>Common</b> (1% to 10%): Deterioration of general physical health, increased alkaline phosphatase, hypermagnesemia, hypercalcemia, hyperglycemia, neutropenia, hyperkalemia, hypoalbuminemia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion-related reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Infections (e.g., sepsis, necrotizing fasciitis, osteomyelitis)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Uveitis and keratitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (e.g., back pain, musculoskeletal chest pain, musculoskeletal pain and discomfort, myalgia, neck pain) (24%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Pyrexia/tumor associated fever</p><p><b>Uncommon</b> (0.1% to 1%): Immune-related aseptic meningitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (e.g., asthenia, lethargy, malaise) (39%), peripheral edema (e.g., edema, localized edema, edema peripheral, lymphedema, peripheral swelling, scrotal edema, scrotal swelling) (15%), pyrexia/tumor associated fever (14%)</p><p><b>Common</b> (1% to 10%): Embryofetal toxicity<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Acute kidney injury, increased creatinine<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea/exertional dyspnea (24%), cough/productive cough (10%)</p><p><b>Uncommon</b> (0.1% to 1%): Immune-mediated pneumonitis<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What type of drug is Imfinzi?</li>
</ul><h2>More about durvalumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: anti-PD-1 monoclonal antibodies</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Durvalumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
<li>Small Cell Lung Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>